Renovaro Biosciences, Inc. is thrilled to announce the successful completion of a financing round, raising an impressive $15 million to accelerate its groundbreaking advancements in allogenic cell and gene therapies. This innovative biotechnology company is at the forefront of research aimed at revolutionizing treatment options for some of the deadliest cancers while also tackling serious infectious diseases such as HIV and Hepatitis B virus (HBV) infections. The funding will significantly bolster Renovaro's ongoing initiatives, allowing the company to enhance its product development capabilities and expand clinical trials aimed at promoting stronger immune system responses. With a robust pipeline of therapies designed to foster long-term or even life-long cancer remission, Renovaro Biosciences stands as a beacon of hope for patients grappling with conditions that have long eluded effective treatment. The infusion of capital will not only expedite the development of its innovative therapies but also strengthen its position within the biotechnology landscape, paving the way for strategic partnerships and collaborations. As Renovaro continues to push the boundaries of science in search of cures, this funding round represents a significant step forward in fulfilling its mission to eradicate life-threatening diseases and improve patient outcomes worldwide. The investors’ trust in Renovaro's vision reaffirms the potential of its pioneering approaches, making it an exciting time for the company as it embarks on the next phase of its journey to deliver transformative therapies to those in need.
Renovaro Biosciences Inc. Secures $15 Million in Funding to Advance Breakthrough Cell and Gene Therapies
Recently funded · $15.0MBiotechnology
Get the full Renovaro Biosciences Inc. company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
